Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Azilsartan Medoxomil vs. Edarbi in Healthy Adults
NCT06990204Phase 1Not yet recruiting
- Sponsor
- Gedeon Richter Plc
- Start
- Jun 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azilsartan medoxomil in hypertension (HTN) (2 arms), sponsored by Gedeon Richter Plc. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
azilsartan medoxomil
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06990204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990204.